Printer Friendly

DEPRENYL RESEARCH SETS THE FACTS STRAIGHT

 DEPRENYL RESEARCH SETS THE FACTS STRAIGHT
 TORONTO, March 23 /PRNewswire/ -- Deprenyl Research Limited


(NASDAQ: DEPLF; TSE DEP) today stated that a signed article in the weekend Financial Times does not agree with the current market valuation of Deprenyl.
 The company went on to say:
 The article states that 1991 earnings were 23 cents; in fact, 1991 earnings were 41 cents. The article compares Deprenyl's market capitalization to non-pharmaceutical companies for no apparent reason. Compared to other pharmaceutical and biotech companies, Deprenyl's valuation is conservative.
 The article states that Eldepryl prices are higher in Canada. Deprenyl's price to wholesalers in Canada is not higher than the price in the United States.
 Deprenyl has, as previously announced, four exciting new drugs at various stages of clinical development and regulatory approval. The drugs in Deprenyl's pipeline -- Alzene for Alzheimer's sufferers, for example -- are as important a determinant of Deprenyl's valuation by the market as any of its other activities. Alzene has an IND and emergency drug release status. Doral has a pending New Drug Application. ALA Photodynamic Therapy is one of the most promising new forms of treatment for basal cell skin cancers, as is 1-alpha D2 for osteoporosis.
 In addition, Deprenyl has a history of sales, profit and dividend growth. Deprenyl Research expects Eldepryl sales to rise substantially and generic competition is not likely before 1994. Strong progress is being made in researching expanded indications for Eldepryl.
 "Since we went public in 1988 at $1 (after adjustment for stock splits) the Financial Times has regularly downdgraded our stock," Morton P. Shulman, M.D., company co-chairman, noted, and two years ago the Financial Times said that Deprenyl's stock price had then peaked at a level one-third of the current price.
 Shulman stated, "I am confident one year from now our earnings will have continued to rise as well as our dividends. I hope the Financial Times will finally get the facts straight."
 Deprenyl Research Limited is an independent Canadian pharmaceutical company which is building a pipeline of products largely devoted to Parkinson's disease and other neurological conditions.
 -0- 3/23/92 R
 /CONTACT: Morton P. Shulman, M.D., co-chairman; James P. Doherty, president; or Martin Barkin, M.D., executive vice president, 416-537-4372, or fax, 416-537-1653, all of Deprenyl/
 (DEPLF) CO: Deprenyl Research Limited ST: Ontario IN: MTC SU:


GK-CK -- NY049R -- 1028 03/24/92 11:49 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 24, 1992
Words:394
Previous Article:FORD MOTOR COMPANY REPORTS U.S. SALES
Next Article:NBD BANK 'AA/F-1+' STRUCTURED RATINGS AFFIRMED BY FITCH -- FITCH FINANCIAL WIRE --
Topics:


Related Articles
DEPRENYL RESEARCH LIMITED REPORTS EARNINGS
DEPRENYL USA REPORTS RESULTS FOR SECOND QUARTER AND SIX MONTHS ENDING JUNE 30, 1992
DEPRENYL USA, INC. REPORTS RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPT. 30, 1992; EXPECTS TO FILE ITS FIRST INVESTIGATIONAL NEW DRUG
DEPRENYL RESEARCH LIMITED ANNOUNCES FOURTH QUARTER RESULTS TO BE RELEASED MID-FEBRUARY
DEPRENYL USA REPORTS YEAR END 1992 RESULTS; CONFIRMS ALA PHOTODYNAMIC DEVELOPMENT ON SCHEDULE; PROPOSES NAME CHANGE TO DUSA PHARMACEUTICALS
DEPRENYL RESEARCH REPORTS EARNINGS
DEPRENYL USA REPORTS FIRST QUARTER RESULTS ON PLAN INITIAL CLINICAL TRIALS PROCEEDING ON SCHEDULE
MEDICIS REPORTS RETIREMENT OF TWO DEBT OBLIGATIONS
DRAXIS HEALTH INC. REPORTS EARNINGS FOR SECOND QUARTER, FIRST HALF
DRAXIS Announces Results for the Third Quarter Ended September 30, 1996

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters